Diabetes research

The Diabetes Research team works closely with the clinical team in the Diabetes Centre and enables patients and their families to be involved in cutting edge research. Our aim is to improve care for patients with diabetes.

What do we do?

There are many trials for children and adults to choose from.  You may get a chance to try out new medication, devices, or educational courses before they are made available through your routine clinical care.  We also offer trials in the prevention of diabetes, and genetics.

We often work with other specialist areas in order to give you lots of choice and support, such as cardiology, ophthalmology, tissue viability (wound care), and podiatry, and this continues to expand.

We also work closely with Primary Care (your GP practices) to identify patients who may want to participate in a trial run by the specialist diabetes team, who do not usually oversee your care. We have had experience of running diabetes trials in your GP practices locally, which has been a great opportunity for you to take part in research in a convenient location.  We hope to continue to grow this service.

We have achieved several milestones we are very proud of; such as first to recruit to target nationally, first site to set up, and top UK and international recruiter.

Please keep your eyes posted on these pages to see if there is anything you may want to take part in.

Who we are:


Dr Peter Hammond (Adult service)
Dr Sutapa Ray (Adult service)
Dr Deirdre Maguire (Adult service)
Dr Aye Aye Min (Adult service)
Dr Shakeel Rahman (Children’s service)

Research team:

Laura Dinning
Diabetes Research Nurse
Christine Cassidy
Diabetes Research Nurse
Christine Morgan
Paediatric Research Nurse
Helen Permain
Primary Care Research Nurse
Kyla Story
Clinical Trials Assistant
Kelly Nicholson
Clinical Trials Assistant

Diabetes research trials

Recruiting now:

OPTION-DM Trial: Optimal Pathway for Treating neurOpathic paiN in Diabetes Mellitus

Principal Investigator – Dr Maguire

Do you have diabetes and also suffer from painful nerve damage? If so, you might be interested in our research study, OPTION-DM.

This study will look at three commonly used medications to try to find the most effective treatment for painful nerve damage as a result of diabetes.

You may be able to take part if you:

  • Have diabetes;
  • Suffer from painful nerve damage as a result of your diabetes; and
  • Are aged 18 or over.

Painful nerve damage due to diabetes can be treated and you can help. Please contact one of the Research team for further information.


ADDRESS 2 – Newly Diagnosed Type 1 Diabetes

Principal Investigator – Dr Hammond

We are recruiting children (over 5 years) and adults diagnosed with Type 1 Diabetes in the last 6 months to the ADDRESS 2 study. The After Diagnosis Diabetes REsearch Support System aims to provide researchers with a resource of people that can be approached for cutting edge research. There are new studies that require early recruitment / treatment so to make this possible the people that have joined ADDRESS 2 would be approached directly. If you are interested please contact one of the Research team for further information.

TrialNet – Screening for Type 1 Diabetes

Principal Investigators – Dr Hammond (Adults) and Dr Rahman (Children)

TrialNet is an international network of sites across the world, based out of the University of Florida.  This network is dedicated to the study, prevention, and early treatment of Type 1 diabetes.

Pathway To Prevention Trial:
We are recruiting close family members of people who have Type 1 Diabetes because they are likely to be at higher risk of developing it themselves.  The aim of the study is to learn more about how diabetes occurs by looking at early markers of diabetes in the blood.

We offer screening for relatives of people who have Type 1 Diabetes, and monitoring for those found to be at high risk of developing Type 1 Diabetes.

If found to be eligible, there is also the opportunity to take part in trials here at Harrogate that may also prevent or delay the onset of Type 1 Diabetes.

Click here to visit the Pathway to Prevention Study website. 

Abatacept Trial:
This trial is for people who are found to be high risk of developing Type 1 Diabetes.

The purpose of the study is to see if giving a medication called abatacept can help delay or prevent the development of abnormal glucose levels and diabetes in people who have markers associated with risk of type 1 diabetes (autoantibodies).

Click here to visit the Abatacept study website.

LIFT Trial:

This trial is for patients who develop Type 1 Diabetes while in one of our TrialNet studies. The LIFT Study (Long-Term Investigative Follow-Up in TrialNet) gives participants personal ongoing monitoring by experts at the forefront of T1D research.

This is the only clinical study in the world that is following people with Type 1 Diabetes before, during and after diagnosis.

Long-term follow up will help us answer questions about what happens in the stages of T1D.

Click here to visit the LIFT study website.


Twitter: @T1D_TrialNet

Facebook: DiabetesTrialNet



In follow-up (closed to recruitment):

Diabetes Prevention using SMS technology

Principal Investigator – Laura Dinning

This trial recruited patients from GP practices with known pre-diabetes (impaired glucose tolerance based on blood tests screening for diabetes called an HbA1c).

Patients are followed up for two years following initial education on diet and lifestyle advice then randomised to receive three times weekly text messages providing lifestyle advice, or not.

This trial was sponsored by Imperial College, London


Principal Investigator – Dr Hammond

This was an observational trial for patients with Type 1 and Type 2 Diabetes who were identified as clinically appropriate to commence Insulin Degludec (Tresiba).  It is investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus.

It followed patients before and after treatment commenced. Follow up was for 12 months.

This trial was sponsored by Novo Nordisk.

Trials that have completed follow-up and are awaiting results:

Date closed


Principal Investigator – Dr Ray

This trial recruited patients with Type 1 Diabetes on insulin pump therapy, to use a new insulin. Follow up was for six months.

This was sponsored by Novo Nordisk®.

April 2017

Leucopatch 2

Principal Investigator – Dr Maguire

This trial set out to demonstrate whether the application of LeucoPatch® (a novel wound care product produced from the patient’s own venous blood, the final product comprising of a thin circular plug) used in conjunction with usual care is superior to usual care alone. Follow up was for six months.

This was sponsored by Nottingham Clinical Trials Unit.

May 2017


Principal Investigator – Dr Hammond

This pilot trial involved delivery of the ‘WICKED’ course to people aged 16-25 transitioning from paediatric to adult diabetes services.

Working with insulin, carbohydrates, ketones and exercise to manage diabetes: exploration of potential for implementation into clinical practice. Follow up after course attendance was for 12 months.

Click this link to find out about the WICKED course.

This was sponsored by the Sheffield Clinical Trials Unit.

February 2017


Principal Investigator – Dr Hammond

This trial recruited patients with Type 2 Diabetes who required optimisation of their long acting insulin regimen.  This was a ‘real world’ observational trial comparing lixisenatide to other injectable intensification therapy.

This trial was sponsored by Sanofi Aventis.

August 2016
Principal Investigator – Dr Hammond
For this trial we recruited patients from GP practices with Type 2 diabetes. This was a dose-finding trial where patients were randomised to doses of daily semaglutide or liraglutide or placebo.  This is a GLP-1 medication, a class of injectable medication used to treat Type 2 diabetes and associated with weight reduction. Patients were followed up for 6 months. This trial was sponsored by Novo Nordisk.
August 2016

Other trials completed:

Medtronic user-evaluation of X54 insulin pump
Predictive Study
UK Diabetes in Universities

Contact us

Address: Research Office, Top Floor, 19 Wetherby Rd, Harrogate District Hospital, Lancaster Park Road, Harrogate, North Yorkshire, HG2 7SX.

Direct Telephone:    01423 553267
Team email:              hdft.diabetesresearch@nhs.net
Out of hours emergency contact:  01423 885959, ask for the site coordinator
Diabetes Centre:      01423 555345